Related Experiment Video
Updated: Aug 5, 2026
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Targeting Aurora A Kinase Enhance the CDK4/6 Inhibitor Sensitivity in HR+/HER2- Breast Cancer
Juan Wu1,2, Yue Wang3, Honglin Yan1
1Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, China.
Oncology Research
|July 25, 2026
Summary
Targeting Aurora A kinase may overcome resistance to CDK4/6 inhibitors in breast cancer. Combining Aurora A inhibitors with CDK4/6 inhibitors shows synergistic antitumor effects, offering new therapeutic strategies for resistant breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are effective against HR+/HER2- breast cancer.
- Treatment resistance to CDK4/6i remains a significant clinical challenge.
- Understanding resistance mechanisms is crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To investigate the role of Aurora A kinase in CDK4/6 inhibitor resistance.
- To determine if targeting Aurora A kinase can enhance sensitivity to CDK4/6 inhibitors.
- To explore the potential of combination therapy with Aurora A inhibitors and CDK4/6 inhibitors.
Main Methods:
- Developed an Abemaciclib-resistant cell line (MCF7AR).
- Assessed protein levels of p-RB, p-Aurora A, Aurora A, and USP22 in various samples.
- Evaluated the efficacy of Aurora A inhibition using cell viability assays and xenograft experiments.
Main Results:
- CDK4/6i-resistant cells and patient samples showed elevated phosphorylated Aurora A and RB levels.
- High Aurora A activity counteracts spindle assembly checkpoint (SAC)-induced mitotic delay.
- Combined Aurora A inhibitor and CDK4/6 inhibitor therapy demonstrated synergistic antitumor effects in vitro and in vivo.
Conclusions:
- Aurora A kinase contributes to CDK4/6i resistance by promoting mitosis and overcoming SAC delay.
- Aurora A inhibition may induce a synthetic lethal effect in RB-inactivated, CDK4/6i-resistant cells.
- Targeting Aurora A kinase presents a promising strategy to overcome CDK4/6i resistance in breast cancer.
Keywords:
Aurora A kinaseCDK4/6i resistanceRB phosphorylationspindle assembly checkpointubiquitinationMore Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...